This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Arthritis Therapeutics Market To 2018 - Novel Oral JAK Inhibitors And Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications

Figure 30: Arthritis Therapeutics Market-Psoriatic Arthritis Therapeutics Market, Global R&D Pipeline by Phase (%), 2011 95

Figure 31:Arthritis Therapeutics Market, Ankylosing Spondylitis Therapeutics Market, Global R&D Pipeline by Phase (%), 2011 96

Figure 32:Arthritis Therapeutics Market, Global, Market Share of Top Six Companies (%), 2010 104

Figure 33:Arthritis Therapeutics Market, SWOT Analysis, Roche, 2011 106

Figure 34: Arthritis Therapeutics Market, SWOT Analysis, Johnson and Johnson Inc., 2011 107

Figure 35: Arthritis Therapeutics Market, SWOT Analysis, Pfizer, 2011 109

Figure 36: Arthritis Therapeutics Market, SWOT Analysis, Abbott Laboratories, 2011 110

Figure 37: Arthritis Therapeutics Market, SWOT Analysis, Bristol-Myers Squibb, 2011 111

Figure 38: Arthritis Therapeutics Market, SWOT Analysis, Amgen, 2011 112

Figure 39: Arthritis Therapeutics Market, Global, Major Licensing Agreements By Geography, 2009-2011 132

Figure 40: Arthritis Therapeutics Market, Global, Major Licensing Agreements by Value (%), 2009-2011 133

Figure 41: GBI Research Market Forecasting Model 139

Companies Mentioned

Roche

Johnson & Johnson

Pfizer

Abbott Laboratories

Bristol- Myers Squibb

Amgen

To order this report: Therapy Industry: Arthritis Therapeutics Market to 2018 - Novel Oral JAK Inhibitors and Biologic Disease Modifying Anti-Rheumatic Drugs (DMARD) Will Drive Continued Growth Across Key Indications

__________________________

Contact Clare: clare@reportlinker.com US:(339) 368 6001Intl:+1 339 368 6001

SOURCE Reportlinker

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
7 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,733.65 +103.38 0.59%
S&P 500 2,106.18 +12.93 0.62%
NASDAQ 5,100.5090 +11.3030 0.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs